Stockscreener 앱 받기
8.01
8.08%
0.5991
전일 마감가:
$7.4109
열려 있는:
$7.61
하루 거래량:
3,264
Relative Volume:
0.50
시가총액:
$35.87M
수익:
$2.61M
순이익/손실:
$1.69M
주가수익비율:
26.67
EPS:
0.3003
순현금흐름:
-
1주 성능:
+0.75%
1개월 성능:
-3.84%
6개월 성능:
-12.27%
1년 성능:
-17.85%
1일 변동 폭
$7.61
$7.98
1주일 범위
$7.346
$8.1933
52주 변동 폭
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
명칭
Daxor Corporation
전화
212-330-8500
주소
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
DXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
7.98 | 35.87M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
466.91 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
195.96 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.04 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
210.05 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
78.28 | 15.83B | 3.90B | 392.30M | 288.10M | 1.95 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-05-16 | 개시 | Ascendiant Capital Markets | Buy |
Daxor Corporation 주식(DXR)의 최신 뉴스
(DXR) Trading Report - news.stocktradersdaily.com
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic - GlobeNewswire
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo - The Manila Times
Duke Research Reveals Why Daxor's Blood Test Outperforms Traditional Heart Failure Methods - Stock Titan
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks - GlobeNewswire
Daxor Expands to 3 New Locations in New Jersey, Midwest - MarketScreener
Breakthrough Blood Volume Tech With 98% Accuracy Gains Major Healthcare Adoption - Stock Titan
Daxor CEO Michael Feldschuh purchases $8,130 in company shares - Investing.com
Daxor CEO Michael Feldschuh purchases $8,130 in company shares By Investing.com - Investing.com UK
Daxor CEO Feldschuh buys shares worth $5,273 By Investing.com - Investing.com Canada
Daxor CEO Feldschuh buys shares worth $5,273 - Investing.com
Ascendiant Capital Markets Issues Positive Forecast for Daxor (NASDAQ:DXR) Stock Price - The AM Reporter
Daxor (NASDAQ:DXR) Given New $25.00 Price Target at Ascendiant Capital Markets - Defense World
(DXR) Investment Analysis and Advice - Stock Traders Daily
Daxor Corporation Reports Strong 2024 Financial Growth - TipRanks
Daxor CFO Michel Robert J purchases $8,000 in company stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases $25,804 in company stock - Investing.com
Daxor CFO Michel Robert J purchases $8,000 in company stock - Investing.com
Daxor Corporation Reports Robust Growth in Earnings Call - TipRanks
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth - Investing.com India
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth By Investing.com - Investing.com UK
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire
Daxor Corporation (DXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.66%
0.58%
자본화:
|
볼륨(24시간):